As schematically illustrated in Figure 7, we hypothesized that the balance between PlGF and sFlt-1 is disturbed when sFlt-1 is downregulated due to proposed triggers such as uremic toxins and reactive oxygen species in CKD patients, leading to the relative activation of atherogenic PlGF signaling through Flt-1. This evidence concerns the gene FLT1 and chronic kidney disease.